SecBot SecBot
8-K ·Filed Apr 2, 2026

BDX

BECTON DICKINSON & CO
NEUTRAL
Impact 4/10
Horizonmonths Processed7mo ago SEC0001628280-26-023185
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

This filing provides a recast historical baseline for New BD post-separation. The unchanged FY2026 guidance and the Q1 adjusted EPS decline of ~10% YoY warrant monitoring the next quarterly report for revenue and margin trajectory under the new segment structure.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$155.23
T+0 close · Apr 2, 2026 · via day close
Latest settled
−1.50%
T+60 · $152.90
Vs SPY
−14.68%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 6 $155.23entry
  2. T+1 · 7mo ago −0.17%α −0.23% · $154.96
  3. T+5 · 7mo ago +0.13%α −4.00% · $155.43
  4. T+20 · 7mo ago −5.85%α −14.83% · $146.15
  5. T+60 · 5mo ago −1.50%α −14.68% · $152.90
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

BD filed recast historical financial information reflecting the spin-off of its Biosciences and Diagnostic Solutions business (completed Feb 9, 2026) as discontinued operations. The recast New BD continuing operations show Q1 fiscal 2026 revenue of $4.486B, up 3.5% reported and 2.5% on a currency-neutral basis versus the prior-year recast period, with adjusted diluted EPS from continuing operations of $2.50, down from $2.78 in the year-ago period.

Key Financial Metrics

EPS (Adj.)
$2.50
GAAP: $1.09
Revenue
$4.5B
est $4.7B · -3.9% · +3.5% YoY
Guidance
low single-digit plus (FXN)
maintained

Key Facts

  • BD completed the spin-off of its Biosciences and Diagnostic Solutions business and combination with Waters Corporation on February 9, 2026.
  • Recast New BD continuing operations Q1 fiscal 2026 revenue: $4.486B, up 3.5% reported and 2.5% FXN vs. $4.333B in the prior-year recast period.
  • Recast New BD continuing operations adjusted diluted EPS (non-GAAP) for Q1 fiscal 2026: $2.50, down from $2.78 in the prior-year recast period.
  • GAAP diluted EPS from continuing operations for recast New BD: $1.09 vs. $0.50 in the prior-year recast period.
  • Full-year fiscal 2026 New BD guidance maintained: adjusted diluted EPS of $12.35 to $12.65 and low single-digit revenue growth (FXN).

Financial Impact

Recast Q1 FY2026 New BD revenue $4.486B (+3.5% reported); adjusted diluted EPS $2.50 (-10.1% vs $2.78 prior year). FY2026 guidance unchanged: adjusted EPS $12.35-$12.65.

revenueeps

Risk Factors

  • Adjusted diluted EPS from continuing operations declined 10.1% YoY in the recast Q1 period.
  • Life Sciences segment (now discontinued) contributed $766M in revenue in Q1 FY2026; its removal reduces the top line and may alter growth comparisons going forward.
  • The recast financials are unaudited and may be subject to revision.

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001628280-26-023185
Document: bdx-20260402.htm0001628280-26-023185
Document: 0001628280-26-023185-index-headers.html0001628280-26-023185
Document: 0001628280-26-023185-index.html0001628280-26-023185
Document: 0001628280-26-023185.txt0001628280-26-023185
8-K Data (Synthetic)0001628280-26-023185

Track record

17 reports on BDX

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 10, 20265d ago 144 Neutral 2/10 Entry $214.52 Now $216.47 +0.91% settles Nov 18
  2. Nov 6, 202610d ago Institutional Cluster Neutral 3/10 Entry $211.88 to $218.03 Now $216.47 +2.17% ▲ +2.90% +0.31% vs SPY
  3. Nov 5, 202611d ago 144 Neutral 2/10 Entry $211.88 to $218.03 Now $216.47 +2.17% ▲ +2.90% +0.31% vs SPY
  4. Nov 5, 202611d ago 8-K Bullish 6/10 Entry $213.55 to $215.71 Now $216.47 +1.37% ▲ +1.01% −2.28% vs SPY
  5. Nov 5, 202611d ago Press Release Neutral 3/10 Entry $213.55 to $215.71 Now $216.47 +1.37% ▲ +1.01% −2.28% vs SPY
  6. Nov 4, 202612d ago Press Release Neutral 2/10 Entry $209.19 to $214.52 Now $216.47 +3.48% ▲ +2.55% +3.46% vs SPY
  7. Oct 26, 202621d ago 144 Neutral 2/10 Entry $195.03 to $198.17 Now $216.47 +10.99% ▲ +1.61% +3.60% vs SPY
  8. Oct 6, 20265w ago Press Release Neutral 2/10 Entry $180.30 to $187.37 Now $216.47 +20.06% ▲ +3.92% +4.06% vs SPY
  9. Aug 14, 202613w ago Insider Cluster Neutral 2/10 Entry $182.09 to $190.74 Now $216.47 +18.88% ▲ +4.75% +5.94% vs SPY
  10. Jul 22, 202616w ago 8-K Neutral 2/10 Entry $153.16 to $168.40 Now $216.47 +41.34% ▲ +9.95% +12.35% vs SPY
Showing 10 of 17

US Market Status

Market Closed · Opens Tue (16h 41m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 21, 2026